| Typicality: | 0.374 |
| Saliency: | 0.348 |
| over the next few years | 6 | temporal |
| with type 2 diabetes | 6 | other |
| with cancer | 5 | other |
| drug → be developed for → use | 15 |
| drug → be developed for → people | 12 |
| drug → be developed for → human use | 4 |
| drug → be developed to treat → people | 4 |
| drug → be developed for → human | 3 |
| drug → be developed for → this purpose | 3 |
| negative | neutral | positive |
| 0.228 | 0.593 | 0.179 |
| Raw frequency | 41 |
| Normalized frequency | 0.348 |
| Modifier score | 0.425 |
| Perplexity | 124.528 |